Clinical Trial

QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this randomized, double-blind, placebo-controlled phase II clinical trial is to investigate the safety and efficacy of QLS12010 in subjects with moderate-to-severe rheumatoid arthritis.The main questions it aims to answer are: • Efficacy and safety of QLS12010 in participants with rheumatoid arthritis. Participants will be randomly allocated to four treatment groups at a 1:1:1:1 ratio to compare the efficacy and safety of different dosages of QLS12010 Capsules against the placebo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-22.
Trial Details
NCT Number NCT07377773
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Rheumatoid Arthritis (RA)
Enrollment 180 participants
Start Date 2026-03-05
Primary Completion 2028-03-05 (estimated)
Study Completion 2028-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-02